MIRA INFORM REPORT

 

 

Report Date :

24.02.2014

 

IDENTIFICATION DETAILS

 

Name :

PAR FORMULATIONS PRIVATE LIMITED (w.e.f. 21.02.2012)

 

 

Formerly Known As :

EDICT PHARMACEUTICALS PRIVATE LIMITED (w.e.f.23.04.2010)

 

NOVEL THERAPEUTICS PRIVATE LIMITED (w.e.f. 24.09.2007)

 

CHK ELECTRONIKS PRIVATE LIMITED

 

 

Registered Office :

Old No. 1/63, New No. 1/58, Padupakkam Village, Via. Vandalur-Kekambakkam Road, Kelambakkam, Chennai – 603103, Tamilnadu

 

 

Country :

India

 

 

Financials (as on) :

31.03.2013

 

 

Date of Incorporation :

22.09.1982

 

 

Com. Reg. No.:

18-009602

 

 

Capital Investment / Paid-up Capital :

Rs.10.607 Millions

 

 

CIN No.:

[Company Identification No.]

U33111TN1982PTC009602

 

 

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Subjected is engaged in the business of developing and manufacturing generic branded drugs.

 

 

No. of Employees :

Not Divulged

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba (46)

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

USD 3431000

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

Usually correct

 

 

Litigation :

Clear

 

 

Comments :

Subject is an established company having satisfactory track record.

 

Sales of the company has increased in 2013 as company has completed its first full year of operation as contract manufacturer and research and development service provider to holding company.

 

However. Trade relations are reported to be fair. Business is active. Payments are reported to be usually correct.

 

The company can be considered normal for business dealing at usual trade terms and conditions.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – December 1, 2013

 

Country Name

Previous Rating

(30.09.2013)

Current Rating

(01.12.2013)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

INDIAN ECONOMIC OVERVIEW

 

The worst is over for India’s economy with gross domestic product likely to expand 5 %to 5.5 % this year and more than 6 % in 2015, according to Moody’s Analytics. Concerns over the rupee and current account deficit are under control, said the agency. Ratings firm Crisil has forecast 6 % growth for 2014/15 up from the estimated 4.8 % for 2013/14.  Total economic growth, infrastructure bottlenecks and lack of transparency and consistency in foreign direct investment policies seem to have taken a toll on India’s attractiveness as an investment destination, says an Ernst & Young survey.  Projects with FDI component fell 16.4 % across the globe in 2012 from the previous year.  The drop in India was steeper at 21 %. State run carrier Air India is doling out free tickets to its 24000 employees, even as it expects to incur a loss of Rs 39000 mn this financial year and has a debt of Rs 350000 mn. 550000 number of jobs generated across India in 2013, a fall of 0.4 % as compared to with a year earlier. The National  Capital Region has a one-fourth share in total jobs created, according to a study by industry lobby group Assochem, Banks, real estate, automobile and telecommunications sectors are showing a rise of job creation. $ 805 mn investments by venture capital firms in India during 2013, registering a drop of about 18 % over the previous year. The Information Technology and IT-Enabled  Services Industry retained its status as the favourable venture capital investors in 2013. Pakistan has temporarily banned gold imports for the second time in six months, as it tries to stem smuggling into India. India’s import duty on gold is 10 % and curbs on purchases have dried up legal imports into what used to be the world’s biggest bullion buyers. The World Gold Council puts the amount smuggled into India at upto 200 tonnes in 2013. The Reserve Bank of India has proposed that unclaimed bank deposits estimated to be about Rs 35000 mn be used for education and awareness among depositors.  According to the plan, deposits that have not been claimed for at least 10 years will be transferred to the scheme.

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

 

 

INFORMATION DENIED

 

MANAGEMENT NON CO-OPERATIVE (91-44-67480000)

 

 

LOCATIONS

 

Registered Office / Research and Development and Manufacturing / Unit:

Old No. 1/63, New No. 1/58, Padupakkam Village, Via. Vandalur-Kekambakkam Road, Kelambakkam, Chennai – 603103, Tamilnadu, India

Tel. No.:

91-44-67480000 / 27474516 / 27474516 / 27474517 / 27474518

Fax No.:

91-44-27474519

E-Mail :

marian.gustafson@parpharm.com

Website :

www.parpharma.com

 

 

DIRECTORS

 

As on 27.09.2013

 

Name :

Mr. Thomas Joseph Haughey

Designation :

Director

Address :

22 Spring Garden Drive, Madison, New Jersey

Date of Birth/Age :

01.12.1963

Date of Appointment :

31.12.2012

DIN No.:

03555315

Other Directorship:

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

1

U33111TN1982PTC009602

PAR FORMULATIONS PRIVATE LIMITED

Director

31/12/2012

17/02/2012

-

Active

 

 

Name :

Mr. Paul Victor Campanelli

Designation :

Director

Address :

7 Cheyenne Court, Oakland, New Jersey

Date of Birth/Age :

10.03.1962

Date of Appointment :

31.12.2012

DIN No.:

03559887

Other Directorship:

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U33111TN1982PTC009602

PAR FORMULATIONS PRIVATE LIMITED

Director

31/12/2012

17/02/2012

-

Active

NO

 

 

Name :

Mr. Venkatesh C

Designation :

Alternative Director

Address :

M 31, Heera Apartment, Jigani Industrial Area, Jigani, Anekal, Bangalore – 562106, Karnataka, India

Date of Birth/Age :

01.06.1968

Date of Appointment :

31.12.2012

DIN No.:

05226939

Other Directorship:

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U33111TN1982PTC009602

PAR FORMULATIONS PRIVATE LIMITED

Alternate director

31/12/2012

14/03/2012

-

Active

NO

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on 27.09.2013

 

Names of Shareholders

No. of Shares

Par Pharmaceutical Inc., U.S.A.

106066

Par Inc., U.S.A.

1

 

 

Total

106067

 


As on 27.09.2013

 

Equity Share Break up (Percentage of Total Equity)

 

Category

Percentage of Holding

Foreign holdings( Foreign institutional investor(s), Foreign companie(s) Foreign financial institution(s), Non-resident Indian(s) or Overseas Corporate bodies or Others

100.00

Total

100.00

 

 

 

 

BUSINESS DETAILS

 

Line of Business :

Subject is engaged in the business of developing and manufacturing generic branded drugs.

 

 

GENERAL INFORMATION

 

No. of Employees :

Not Divulged

 

 

Bankers :

State Bank of India, Overseas Branch, No. 86. Rajaji Salai, Chennai – 600001, Tamilnadu, India

 

Banking Relations :

--

 

 

Auditors :

 

Name :

Deloitte Haskins and Sells

Chartered Accountants

Address :

ASV N Ramana Tower, 52, Venkatnarayana Road, T Nagar, Chennai – 600017, Tamilnadu, India

Tel. No.:

91-44-66885000

Fax No.:

91-44-66885050

PAN No.:

AACFD3771D

 

 

Ultimate Holding Company:

·         Par Pharmaceuticals Companies Inc (From February 17, 2012)

 

 

Holding Company:

·         Par Pharmaceuticals Inc (From February 17, 2012)

 

 

Companies where KMPs are interested (Upto February 16, 2012):

·         Clan Laboratories Private Limited

·         Delvin Formulations Private Limited

 

 

CAPITAL STRUCTURE

 

As on 31.03.2013

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

145000

Equity Shares

Rs.100/- each

Rs.14.500 Millions

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

106067

Equity Shares

Rs.100/- each

Rs.10.607 Millions

 

 

 

 

 


 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2013

31.03.2012

31.03.2011

I.        EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

10.607

6.307

13.809

(b) Reserves & Surplus

847.252

549.680

166.085

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

215.679

6.500

Total Shareholders’ Funds (1) + (2)

857.859

771.666

186.394

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

0.000

0.000

155.681

(b) Deferred tax liabilities (Net)

5.767

2.951

0.000

(c) Other long term liabilities

0.000

0.000

0.000

(d) long-term provisions

0.000

0.000

0.000

Total Non-current Liabilities (3)

5.767

2.951

155.681

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

0.000

0.000

33.373

(b) Trade payables

53.679

39.168

33.718

(c) Other current liabilities

70.557

10.597

50.326

(d) Short-term provisions

11.181

197.558

0.000

Total Current Liabilities (4)

135.417

247.323

117.417

 

 

 

 

TOTAL

999.043

1021.940

459.492

 

 

 

 

II.    ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

276.850

213.576

196.363

(ii) Intangible Assets

1.109

3.261

194.559

(iii) Capital work-in-progress

123.974

8.128

0.000

(iv) Intangible assets under development

0.000

0.000

47.954

(b) Non-current Investments

0.000

0.000

0.000

(c) Deferred tax assets (net)

0.000

0.000

0.000

(d)  Long-term Loan and Advances

3.004

14.945

2.317

(e) Other Non-current assets

2.749

2.974

0.000

Total Non-Current Assets

407.686

242.884

441.193

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

220.733

56.118

13.021

(c) Trade receivables

350.248

45.217

0.000

(d) Cash and cash equivalents

16.774

18.743

0.310

(e) Short-term loans and advances

3.491

6.130

4.900

(f) Other current assets

0.111

652.848

0.068

Total Current Assets

591.357

779.056

18.299

 

 

 

 

TOTAL

999.043

1021.940

459.492

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

 

31.03.2013

31.03.2012

31.03.2011

 

 

 

 

 

 

ORDINARY INCOME

517.700

57.960

25.480

 

INCOME FROM SALE OF ITANGIBLE NET OF WRITE OFF

0.000

608.310

0.000

 

TOTAL

517.700

666.270

25.480

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Office Expenses

 

 

 

Administrative Expenses

 

 

 

 

 

Advertising Expenses

 

 

 

 

 

TOTAL                                    

385.700

104.690

26.990

 

 

 

 

 

 

PROFIT/ (LOSS)  BEFORE TAX

132.000

561.580

(1.510)

 

 

 

 

 

Less

TAX                                                                 

45.810

192.050

1.200

 

 

 

 

 

 

PROFIT/ (LOSS)  AFTER TAX

86.190

369.530

(2.710)

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

 

Revenue from research and development services

341.395

38.090

25.260

 

 

Revenue from manufacturing services

126.838

9.008

0.000

 

 

Interest on sale consideration due

48.929

10.779

--

 

 

Consideration for transfer of IP rights capabilities and resources

0.000

972.000

0.000

 

TOTAL EARNINGS

517.162

1019.098

25.260

 

 

 

 

 

 

IMPORTS

 

 

 

 

 

Raw Materials

90.388

3.689

8.215

 

 

Capital Goods

54.133

21.383

25.175

 

TOTAL IMPORTS

144.521

25.072

33.390

 

 

 

 

 

 

Earnings Per Share (Rs.)

812.60

3483.93

(25.55)

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2013

31.03.2012

31.03.2011

PAT / Total Income

(%)

16.65

55.46

(10.63)

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

15.08

55.39

(0.37)

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.15

0.73

(0.01)

 

 

 

 

 

Debt Equity Ratio

(Total Debt/Networth)

 

0.00

0.00

0.00

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

4.37

3.15

0.15

 

 

FINANCIAL ANALYSIS

[all figures are in Rupees Millions]

 

 

DEBT EQUITY RATIO

 

Particular

31.03.2011

31.03.2012

31.03.2013

 

(INR in Mlns.)

(INR in Mlns.)

(INR in Mlns.)

Share Capital

13.809

6.307

10.607

Reserves & Surplus

166.085

549.680

847.252

Net worth

179.894

555.987

857.859

 

 

 

 

long-term borrowings

155.681

0.000

0.000

Short term borrowings

33.373

0.000

0.000

Total borrowings

189.054

0.000

0.000

Debt/Equity ratio

1.051

0.000

0.000

 

 

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2011

31.03.2012

31.03.2013

 

(INR in Mlns)

(INR in Mlns)

(INR in Mlns)

Ordinary Income

25.480

57.960

517.700

 

 

127.473

793.202

 

 

 

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2011

31.03.2012

31.03.2013

 

(INR in Mlns)

(INR in Mlns)

(INR in Mlns)

Ordinary Income

25.480

57.960

517.700

Profit

(2.710)

369.530

86.190

 

(10.64%)

637.56%

16.65%

 

 

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

No

9]

Name of person contacted

No

10]

Designation of contact person

No

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

-----

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

Yes

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

No

20]

Export / Import details (if applicable)

No

21]

Market information

-----

22]

Litigations that the firm / promoter involved in

-----

23]

Banking Details

Yes

24]

Banking facility details

No

25]

Conduct of the banking account

-----

26]

Buyer visit details

-----

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

Yes

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

Yes

32]

PAN of Proprietor/Partner/Director, if available

No

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

No

 

 

NOTE:

 

The Registered address of the company has been shifted from 2, May Flower Garden, Srinivasa Avenue Raja Annamalai Puram, Chennai – 600023, Tamilnadu, India to the present address w.e.f 14.08.2007

 

 

INDEX OF CHARGES

 

No Charges Exist for Company

 

 

CORPORATE INFORMATION

 

The Company is engaged in the business of developing and manufacturing generic branded drugs. The Company is an Export Oriented Unit (EOU). Effective February 17, 2012, the Company undertakes contract manufacturing activities and performs Research and Development activities on behalf of Par Pharmaceuticals Inc. USA ("PAR US" / "the Holding Company") on a cost plus basis.

 

 

PERFORMANCE REVIEW

 

This was the first full year of operation as Contract Manufacturer and Research and Development Service provider to Par Pharmaceuticals Inc. the Holding company. Sale of Intangibles last year is a one-time activity hence there is no sale of intangible in the current financial year. The company has made a strong beginning after the change in management. This brings a lot of promise for the future of the company.

 

 

BUSINESS

 

The company continued with the activities of developing and filing and as under the direction and control of the Holding Company. The company has tech-transferred few products from the holding company for the commercial manufacturing operations during the year. The company is well poised to increase its commercial production with the expansion plans of its facility and planned investment in additional Equipments.

 

 

FIXED ASSETS

 

¨       Building

¨       Plant and Equipment

¨       Furniture and Fixture

¨       Vehicles

¨       Computers

¨       Office Equipment

 

 

 


 

CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                              None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.16

UK Pound

1

Rs.103.44

Euro

1

Rs.85.27

 

 

INFORMATION DETAILS

 

Information Gathered by :

NYA

 

 

Report Prepared by :

ANK

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

6

PAID-UP CAPITAL

1~10

5

OPERATING SCALE

1~10

5

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

5

--PROFITABILIRY

1~10

5

--LIQUIDITY

1~10

5

--LEVERAGE

1~10

5

--RESERVES

1~10

5

--CREDIT LINES

1~10

5

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

NO

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

TOTAL

 

46

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.